| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular basis of resistance to azole antifungals.
|
Trends Mol Med
|
2002
|
2.48
|
|
2
|
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
|
Cancer Res
|
2006
|
2.38
|
|
3
|
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
|
Cancer Res
|
2010
|
2.22
|
|
4
|
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
|
Expert Opin Ther Targets
|
2012
|
1.99
|
|
5
|
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
|
Clin Cancer Res
|
2008
|
1.95
|
|
6
|
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
|
J Clin Endocrinol Metab
|
2010
|
1.68
|
|
7
|
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
|
Mol Cancer
|
2011
|
1.59
|
|
8
|
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
|
Mol Cancer Ther
|
2009
|
1.57
|
|
9
|
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
|
Drug Resist Updat
|
2003
|
1.54
|
|
10
|
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
|
J Clin Oncol
|
2004
|
1.48
|
|
11
|
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
|
Clin Cancer Res
|
2008
|
1.46
|
|
12
|
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
|
J Clin Endocrinol Metab
|
2010
|
1.44
|
|
13
|
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
|
BJU Int
|
2008
|
1.41
|
|
14
|
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.
|
Clin Pharmacol Ther
|
2002
|
1.39
|
|
15
|
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.
|
Cancer Metastasis Rev
|
2012
|
1.39
|
|
16
|
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
|
Mol Pharmacol
|
2008
|
1.37
|
|
17
|
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
|
Mol Pharmacol
|
2005
|
1.31
|
|
18
|
Periorbital necrotising fasciitis.
|
Br J Ophthalmol
|
2009
|
1.28
|
|
19
|
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2002
|
1.27
|
|
20
|
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2011
|
1.25
|
|
21
|
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
|
J Exp Clin Cancer Res
|
2010
|
1.23
|
|
22
|
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
|
Mol Cancer Ther
|
2006
|
1.20
|
|
23
|
Polycomb genes and cancer: time for clinical application?
|
Crit Rev Oncol Hematol
|
2011
|
1.19
|
|
24
|
Pharmacological issues of linezolid: an updated critical review.
|
Clin Pharmacokinet
|
2010
|
1.16
|
|
25
|
Promoting predictive, preventive and personalised medicine: European event of global importance.
|
EPMA J
|
2011
|
1.14
|
|
26
|
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
|
Mol Cancer Ther
|
2008
|
1.13
|
|
27
|
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
|
Clin Cancer Res
|
2004
|
1.11
|
|
28
|
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
|
J Pharm Sci
|
2007
|
1.09
|
|
29
|
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
|
Int J Cancer
|
2011
|
1.08
|
|
30
|
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
|
J Clin Pharmacol
|
2004
|
1.08
|
|
31
|
Breast lymphomas around breast implants.
|
Ann Surg
|
2014
|
1.07
|
|
32
|
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2009
|
1.06
|
|
33
|
The pharmacological bases of the antiangiogenic activity of paclitaxel.
|
Angiogenesis
|
2013
|
1.05
|
|
34
|
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
|
Crit Rev Oncol Hematol
|
2011
|
1.04
|
|
35
|
Cancer stem cell epigenetics and chemoresistance.
|
Epigenomics
|
2009
|
1.03
|
|
36
|
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
|
Pharmacogenomics
|
2013
|
1.02
|
|
37
|
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
38
|
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
|
Curr Drug Metab
|
2011
|
1.01
|
|
39
|
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.
|
Ther Drug Monit
|
2010
|
1.01
|
|
40
|
Antimicrobial peptides: therapeutic potential for the treatment of Candida infections.
|
Expert Opin Investig Drugs
|
2002
|
0.99
|
|
41
|
Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.
|
Pharmacogenomics
|
2007
|
0.98
|
|
42
|
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
|
Mol Cancer Ther
|
2012
|
0.98
|
|
43
|
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
|
Drug Resist Updat
|
2011
|
0.98
|
|
44
|
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
|
Angiogenesis
|
2012
|
0.96
|
|
45
|
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
|
Clin Cancer Res
|
2008
|
0.96
|
|
46
|
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
|
Clin Cancer Res
|
2006
|
0.96
|
|
47
|
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
|
Clin Pharmacol Ther
|
2006
|
0.94
|
|
48
|
Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?
|
Drugs Aging
|
2010
|
0.94
|
|
49
|
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
|
Mol Cancer Ther
|
2010
|
0.93
|
|
50
|
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.
|
J Thorac Oncol
|
2011
|
0.93
|
|
51
|
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
|
BMC Cancer
|
2010
|
0.93
|
|
52
|
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
|
Pharmacogenet Genomics
|
2006
|
0.93
|
|
53
|
Cardiac toxicity of antineoplastic anthracyclines.
|
Curr Med Chem Anticancer Agents
|
2003
|
0.93
|
|
54
|
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
|
Mol Cancer Ther
|
2009
|
0.92
|
|
55
|
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
|
Eur J Pharmacol
|
2004
|
0.92
|
|
56
|
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
|
Clin Cancer Res
|
2004
|
0.92
|
|
57
|
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
|
Urology
|
2007
|
0.91
|
|
58
|
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity.
|
Clin Breast Cancer
|
2011
|
0.91
|
|
59
|
The emerging role of histone lysine demethylases in prostate cancer.
|
Mol Cancer
|
2012
|
0.91
|
|
60
|
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
|
Curr Clin Pharmacol
|
2006
|
0.89
|
|
61
|
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
|
Pharmacol Res
|
2007
|
0.88
|
|
62
|
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
|
Target Oncol
|
2013
|
0.88
|
|
63
|
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.
|
Endocr Pract
|
2013
|
0.88
|
|
64
|
Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.
|
Clin Pharmacokinet
|
2013
|
0.88
|
|
65
|
Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin.
|
Antimicrob Agents Chemother
|
2011
|
0.87
|
|
66
|
Histone lysine demethylases in breast cancer.
|
Crit Rev Oncol Hematol
|
2012
|
0.87
|
|
67
|
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.
|
Expert Opin Investig Drugs
|
2015
|
0.87
|
|
68
|
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients.
|
ScientificWorldJournal
|
2012
|
0.86
|
|
69
|
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
|
Pharmacogenomics
|
2011
|
0.86
|
|
70
|
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
|
Oncologist
|
2014
|
0.86
|
|
71
|
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.
|
Pharmacogenomics
|
2012
|
0.85
|
|
72
|
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
|
Eur Urol
|
2008
|
0.85
|
|
73
|
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
|
Cancer Chemother Pharmacol
|
2009
|
0.84
|
|
74
|
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
|
Lab Invest
|
2008
|
0.84
|
|
75
|
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.
|
Int J Antimicrob Agents
|
2013
|
0.83
|
|
76
|
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
|
Eur J Pharmacol
|
2009
|
0.83
|
|
77
|
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
|
J Clin Endocrinol Metab
|
2014
|
0.83
|
|
78
|
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.
|
Invest New Drugs
|
2011
|
0.82
|
|
79
|
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.
|
Br J Clin Pharmacol
|
2008
|
0.82
|
|
80
|
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors.
|
Farmaco
|
2004
|
0.82
|
|
81
|
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
|
J Clin Endocrinol Metab
|
2012
|
0.82
|
|
82
|
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.
|
Pharmacogenomics
|
2009
|
0.82
|
|
83
|
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.
|
Pharmacogenomics
|
2013
|
0.82
|
|
84
|
Pharmacogenetics of neoplastic diseases: new trends.
|
Pharmacol Res
|
2004
|
0.81
|
|
85
|
Pharmacogenetics of anti-estrogen treatment of breast cancer.
|
Cancer Treat Rev
|
2011
|
0.81
|
|
86
|
Refining sorafenib therapy: lessons from clinical practice.
|
Future Oncol
|
2014
|
0.81
|
|
87
|
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
|
Neoplasia
|
2011
|
0.81
|
|
88
|
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
|
Cancer
|
2014
|
0.81
|
|
89
|
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.
|
Neoplasia
|
2012
|
0.81
|
|
90
|
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.
|
J Am Geriatr Soc
|
2010
|
0.81
|
|
91
|
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
|
Expert Rev Mol Diagn
|
2014
|
0.80
|
|
92
|
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
|
Cancer Chemother Pharmacol
|
2006
|
0.80
|
|
93
|
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
|
Biomark Med
|
2012
|
0.80
|
|
94
|
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
|
EPMA J
|
2010
|
0.80
|
|
95
|
Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
|
J Clin Endocrinol Metab
|
2013
|
0.79
|
|
96
|
Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
|
Crit Rev Oncol Hematol
|
2008
|
0.79
|
|
97
|
Ceramide analogues in apoptosis: a new strategy for anticancer drug development.
|
Farmaco
|
2003
|
0.79
|
|
98
|
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.
|
Oncol Lett
|
2013
|
0.79
|
|
99
|
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
|
J Clin Oncol
|
2010
|
0.79
|
|
100
|
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
|
Lung Cancer
|
2011
|
0.78
|
|
101
|
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
|
Pharmacogenomics
|
2014
|
0.78
|
|
102
|
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
|
Ther Drug Monit
|
2002
|
0.78
|
|
103
|
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
|
Curr Cancer Drug Targets
|
2010
|
0.78
|
|
104
|
Molecular targeted treatments for fungal infections: the role of drug combinations.
|
Trends Mol Med
|
2003
|
0.78
|
|
105
|
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition.
|
ChemMedChem
|
2006
|
0.78
|
|
106
|
A benefit-risk assessment of basiliximab in renal transplantation.
|
Drug Saf
|
2004
|
0.78
|
|
107
|
Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
|
Expert Rev Anticancer Ther
|
2011
|
0.78
|
|
108
|
Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?
|
J Clin Oncol
|
2011
|
0.78
|
|
109
|
Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
|
Scand J Infect Dis
|
2011
|
0.77
|
|
110
|
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
|
Anticancer Res
|
2009
|
0.77
|
|
111
|
Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.
|
Clin Pract Epidemiol Ment Health
|
2010
|
0.77
|
|
112
|
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions.
|
J Clin Endocrinol Metab
|
2010
|
0.77
|
|
113
|
Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
|
J Clin Pharmacol
|
2011
|
0.77
|
|
114
|
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
|
Curr Top Med Chem
|
2012
|
0.77
|
|
115
|
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
|
Clin Pharmacol Ther
|
2002
|
0.76
|
|
116
|
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
|
Biochem Pharmacol
|
2011
|
0.76
|
|
117
|
Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
|
Pancreas
|
2007
|
0.76
|
|
118
|
Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal.
|
Heart Lung
|
2012
|
0.76
|
|
119
|
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2003
|
0.76
|
|
120
|
Pharmacogenomics and cancer stem cells: a changing landscape?
|
Trends Pharmacol Sci
|
2011
|
0.76
|
|
121
|
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor.
|
Eur J Pharmacol
|
2003
|
0.76
|
|
122
|
Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter.
|
Clin Cancer Res
|
2012
|
0.75
|
|
123
|
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
|
Eur J Pharmacol
|
2006
|
0.75
|
|
124
|
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
|
J Thorac Oncol
|
2011
|
0.75
|
|
125
|
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
|
Chemotherapy
|
2010
|
0.75
|
|
126
|
Author's reply: To PMID 22443211.
|
Expert Opin Ther Targets
|
2013
|
0.75
|
|
127
|
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
|
Oncology
|
2016
|
0.75
|
|
128
|
The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells.
|
Pharmacol Res
|
2002
|
0.75
|
|
129
|
Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer.
|
Endocrinology
|
2011
|
0.75
|
|
130
|
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase.
|
Curr Pharm Des
|
2017
|
0.75
|
|
131
|
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity.
|
Farmaco
|
2003
|
0.75
|
|
132
|
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
|
Pharmacogenomics
|
2009
|
0.75
|
|
133
|
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo.
|
Oncol Res
|
2017
|
0.75
|
|
134
|
Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|
|
135
|
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.
|
Dig Liver Dis
|
2011
|
0.75
|
|
136
|
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
|
Ther Drug Monit
|
2005
|
0.75
|
|
137
|
Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.75
|
|
138
|
Efficacy and safety of basiliximab in kidney transplantation.
|
Expert Opin Drug Saf
|
2005
|
0.75
|
|
139
|
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
|
Toxicol Appl Pharmacol
|
2005
|
0.75
|
|
140
|
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents.
|
Med Chem
|
2005
|
0.75
|